On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

Diagnosed with leukaemia nearly three decades ago, The Alarm's Mike Peters is now hopeful of "a way to be cured once and for ...

Mike Peters, frontman of Welsh band The Alarm, is in remission from an aggressive cancer after taking part in an experimental ...

The Alarm frontman Mike Peters is in remission after undergoing an innovative blood cancer treatment at. | ITV News Granada ...

The frontman of rock band The Alarm has revealed he is in remission from cancer thanks to an NHS drug trial. Mike Peters was ...

Peters, who has supported U2 and Status Quo on tour, was first diagnosed with chronic lymphocytic leukaemia (CLL) more than ...

The lead singer of rock band The Alarm is in remission from an aggressive cancer thanks to an NHS drug trial. Mike Peters had ...

MIKE Peters, frontman of Rhyl band The Alarm, is in remission from aggressive cancer thanks to an NHS drug trial. The rock star, who was forced to cancel a US tour earlier this year after being ...